title: Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences.
abstract: Buprenorphine is an opioid agonist-antagonist with a 'ceiling effect' for respiratory depression. Compared with methadone, its unique pharmacology offers practical advantages and enhanced safety when prescribed as recommended and supervised by a physician. Buprenorphine has been approved in several countries as an efficient and safe maintenance therapy for heroin addiction. Its use resulted in a salutary effect with a reduction in heroin overdose-related deaths in countries that implemented office-based buprenorphine maintenance. In France, however, where high-dose buprenorphine has been marketed since 1996, several cases of asphyxic deaths were reported among addicts treated with buprenorphine. Death resulted from buprenorphine intravenous misuse or concomitant sedative drug ingestion, such as benzodiazepines. In these situations of abuse, misuse, or in association with elevated doses of psychotropic drugs, buprenorphine may cause severe respiratory depression. Unlike other opiates, the respiratory effects from buprenorphine are not responsive to naloxone. However, the exact mechanism of buprenorphine-induced effects on ventilation is still unknown. The role of norbuprenorphine, the main N-dealkylated buprenorphine metabolite with potent respiratory depressor activity, also remains unclear. Experimental studies investigating the respiratory effects of combinations of high doses of buprenorphine and benzodiazepines suggested that this drug-drug interaction may result from a pharmacodynamic interaction. A pharmacokinetic interaction between buprenorphine and flunitrazepam is also considered. As there are many questions regarding the possible dangers of death or respiratory depression associated with buprenorphine use, we aimed to present a comprehensive critical review of the published clinical and experimental studies on buprenorphine respiratory effects.
authors.affiliation: INSERM U705, CNRS, UMR 7157, Université Paris 7, Université Paris 5, Hôpital Fernand Widal, Paris, France. bruno-megarbane@wanadoo.fr
authors.forename: Bruno
authors.initials: B
authors.lastname: Mégarbane
authors.forename: Raymond
authors.initials: R
authors.lastname: Hreiche
authors.forename: Stéphane
authors.initials: S
authors.lastname: Pirnay
authors.forename: Nicolas
authors.initials: N
authors.lastname: Marie
authors.forename: Frédéric J
authors.initials: FJ
authors.lastname: Baud
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D001237:Asphyxia / Q000139:chemically induced / Q000401:mortality; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D004347:Drug Interactions; D006556:Heroin Dependence / Q000188:drug therapy; D006801:Humans; D012131:Respiratory Insufficiency / Q000139:chemically induced*
chemical_list: D000701:Analgesics, Opioid; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D002047:Buprenorphine